UCB Inspired by patients. Driven by science. 9 month interim report Brussels, 30 October 2018
|
|
- Wilfrid Garrison
- 5 years ago
- Views:
Transcription
1 UCB Inspired by patients. Driven by science. 9 month interim report Brussels, 30 October 2018
2 Disclaimer and safe harbor Forward-looking statements 2 This presentation contains forward-looking statements, including, without limitation, statements containing the words believes, anticipates, expects, intends, plans, seeks, estimates, may, will, and continue and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation. Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions, for circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.
3 UCB's patient value strategy 3 Our ambition is to be the patient preferred biotech leader, creating patient value for specific populations through unique outcomes, the best experience and improving as many of these lives as possible. This will lead to sustainable growth for UCB and its shareholders. Mariana, living with epilepsy Value for patients Value for shareholders
4 Driving value for patients Progress towards higher patient value 4 From Solution to Patient Thanks to innovative extrapolation, faster access for epilepsy patients for Briviact (pediatric) and Keppra (China) Acquisition of midazolam nasal spray in the treatment of acute repetitive seizures (ARS) in patients with epilepsy Partnership with Sciences 37 to bring clinical studies directly into patient s home From Patient to Science Cimzia women of child bearing age approval UCB0107 (anti-tau antibody) first in human From Science to Solution Rozanolixizumab discovery driven by patient experiences with outpatient treatment
5 UCB is progressing on our strategic growth path Achievements 2018 vs. priorities well on track 5 Grow & Prepare 2015 Breakthrough & Lead Accelerate 2022 & Expand 2019 Grow core products Cimzia, Vimpat, Keppra, Briviact + Neupro combined net sales: 2.78 billion (+6%; +12% CER) Advance and prepare launch of next wave Phase 3 program for bimekizumab in psoriasis started Evenity resubmission to U.S. FDA midazolam filing (U.S.) Deliver breakthrough solutions dapirolizumab pegol Phase 2b topline results in lupus rozanolixizumab Phase 2a topline results in myasthenia gravis UCB0107 (anti-tau antibody) first in human Continued focus Creation of Syndesi + investment in Ceribell Acquisitions of Element Genomics + midazolam nasal spray 2018 financial outlook confirmed Refer to slides in the appendix for further details
6 Grow core products On track to deliver FY 2018 guidance 6 million 9M M 2017 Act CER Revenue % 6% Immunology % 9% Cimzia % 9% Adjusted for allergy drug divestiture: +5%; +8% CER Neurology % 14% Vimpat % 19% Keppra % 5% Briviact % 81% Neupro % 2% Combined net sales: 2.78 billion (+6%; +12% CER) Numbers may not add due to rounding CER: constant exchange rate
7 Increasing value of UCB's early and late-stage pipeline Driven by strong UCB science and technology platforms 7 Phase 1 Phase 2a radiprodil infantile spasm UCB0107 UCB0599 UCB6673 UCB7858 rozanolixizumab myasthenia gravis immune thrombocytopenia Phase 2b / Phase 3 dapirolizumab pegol systemic lupus erythematosus padsevonil epilepsy bimekizumab psoriasis, psoriatic arthritis ankylosing spondylitis Filing midazolam nasal spray - acute repetitive seizures romosozumab osteoporosis UCB0159 neurology immunology bone Seletalisib in Sjogren's Syndrome and APDS (phase 2a and phase 1b) deprioritized UCB4144/VR942 available for license
8 Continued focus Complement & share 8 Acquisitions Investment Spin offs Ventures Rapid Response EEG System StrideBio, Inc. midazolam nasal spray in epilepsy UCB acquired rights to midazolam nasal spray from Proximagen in April 2018 UCB invested in Ceribell in September 2018
9 2018 and mid-term guidance confirmed Maximize (new) growth drivers and strengthen sustainability financial targets Mid-term guidance Revenue billion Continued strong core product growth Currency exchange impact rebitda billion R&D expense ratio of ~26% (+/-1% point) Launch preparation Core EPS* Expected underlying tax ratio in the "low twenties" rebitda / revenue ratio of 31% in 2021 UCB investing into the pipeline complemented with inorganic growth opportunities Peak sales 'CVN' combined > 3.1 billion by 2020 Briviact > 600 million in 2026 rebitda: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge * ~188 million shares weighted average outstanding
10 Advance and prepare launch of next products Delivering on strategy, growth and profitability targets 10 Evenity (romosozumab) midazolam nasal spray bimekizumab padsevonil rozanolixizumab Phase 3 program completed Acquired: Phase 3 program completed Phase 2b program completed Phase 2a program completed Proof of concept achieved Regulatory review Regulatory review Phase 3 Phase 2b ongoing Phase 2 ongoing U.S. resubmission of the Biologics License Application (July 2018) EU (Jan. 2018) CDN, JP, AU, BR, CH U.S. filing (Aug 2018) orphan drug + fast track designation granted psoriasis: ongoing (results Q4 2019) psoriatic arthritis to start (Q4 2018) ankylosing spondylitis to start (Q4 2018) highly drug-resistant epilepsy start: Feb (results H1 2020) myasthenia gravis results (Oct 2018) immune thrombocytopenia (ITP) (results Q4 2018) CIDP to start Q Sustainable top and bottom line growth delivered over the last years Profitability target achieved ahead of time in 2017 Strong foundation enabling future growth and investments in innovation The trademark Evenity is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Evenity (romosozumab) is developed in partnership with Amgen globally. UCB acquired rights to midazolam nasal spray from Proximagen in April 2018 CIDP: Chronic inflammatory demyelinating polyneuropathy
11 Further facts and figures 11
12 Grow core products 2018 lifecycle management milestones 12 Cimzia Vimpat Keppra Briviact Neupro WOCBA label extension (EU Jan / U.S. Mar / Japan Sept) Psoriasis (U.S. May / EU June) AutoClick (Japan Aug) Epilepsy GTCS (China May) Epilepsy monotherapy (China July) Epilepsy POS: pediatric (U.S. May / EU July) Parkinson s disease (China July) Rheumatoid arthritis (China Mar) Nr axspa³ (U.S. Sept) Nr axspa³: Phase 3 results (U.S. May) PsO 4 / PsA: Phase 3 results (Japan Sept) Epilepsy POS (Japan): o pediatric (incl. dry syrup formulation - Jan) o IV formulation (Jan) Epilepsy POS (China): o pediatric (incl. oral formulation - Sept) o IV formulation (Sept) Acute repetitive seizures: Phase 2 results (July) WOCBA: women of child bearing age PsO: psoriasis POS: partial onset seizures, also known as focal seizures Nr axspa: non radiographic axial spondyloarthritis PsA: psoriatic arthritis GTCS: primary generalized tonic-clonic seizures
13 Cimzia performance 13 Sustainable growth in all regions Net sales 1 million 9 M M 2017 Act CER For patients living with Rheumatoid arthritis Psoriatic arthritis Psoriasis Ankylosing spondylitis / axial spondyloarthritis Crohn s disease U.S % 7% Europe % 9% International markets % 22% Total Cimzia % 9% Label extension to include WOCBA (EU / U.S. / Japan) Psoriasis: approval (U.S. & EU) AutoClick : approval (Japan) Nr axial spondyloarthritis²: Phase 3 results & filing (U.S.) Psoriasis / psoriatic arthritis: Phase 3 results (Japan) Loss of exclusivity (U.S. & EU) Loss of exclusivity (Japan) 1 Numbers may not add due to rounding 2 nr axspa: non-radiographic axial spondyloarthritis CER: constant exchange rates
14 Cimzia in-market performance 14 U.S. Europe Japan 20% Cimzia vs. Rheumatology Market Growth 1 20% Cimzia vs. Rheumatology Market Growth 1 20% Cimzia vs. RA Market Growth 1 15% 10% 5% 2.6% 6.7% +7.4% 10.0% 15% 10% 5% 10.4% 12.0% -1.3% 9.1% 15% 10% 5% 3.2% 6.3% +7.1% 10.3% 0% Anti TNF Biologics Cimzia 0% Anti TNF Biologics Cimzia 0% Anti TNF Biologics Cimzia 7.0% Cimzia Rheumatology R3M Patient Share 2 9.0% Cimzia Rheumatology R3M Patient Share 2 5.0% Cimzia RA R3M Patient Share 2 6.5% 6.3% 8.5% 8.3% 4.5% 4.4% 6.0% +0.3% 8.0% 4.0% +0.3% 5.5% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source: U.S: IQVIA Source of Business Report Aug % Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source: IMS MIDAS In-Market KPI s are based on Exit Patients 3.5% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source: IMS MIDAS; Cimzia patients are considered 100% in RA In-Market KPI s are based on Exit Patients 1 In-market growth is calculated for MAT period ; US, Europe & Japan : MAT Aug 2018 vs MAT Aug Market share is calculated for R3M period
15 Vimpat 15 Strong growth in all markets Net sales 1 million 9 M M 2017 Act CER For patients living with Epilepsy POS 2 Adults, adolescents and children from 4 years of age (EU & U.S.) Adults (Japan) U.S % 17% Europe % 19% International markets % 50% Total Vimpat % 19% POS 2 pediatric (incl. dry syrup formulation): filing (Japan) IV formulation: filing (Japan) POS 2 pediatric (incl. oral solution): submission (China) IV formulation: submission (China) U.S. Court of Appeals confirms validity of patent PGTCS 3 : Phase 3 results Patent expiry (U.S. & EU) Loss of exclusivity (Japan) 1 Numbers may not add due to rounding 2 POS: Partial-onset seizures, also known as focal seizures CER: constant exchange rate 3 PGTCS: Primary Generalized Tonic-Clonic Seizures
16 Vimpat in-market performance 16 U.S. Vimpat vs. AED Market Growth (TRx) 20% 15% 10% +6.8% 7.9% 5% 1.1% 0% AED Market Vimpat Vimpat R3M TRx Share 4.4% +0.3% 4.8% 4.6% 4.4% 4.2% 4.0% 3.8% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx 20% Europe Vimpat vs. AED Market Growth (TDx) 18.8% 15% 10% +20.9% 5% 0% -2.1% AED Market Vimpat -5% Vimpat R3M TDx Share 4.0% 4.0% 3.8% 3.6% 3.4% +0.8% 3.2% 3.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data EU: IMS MIDAS - In-Market KPI s are based on TDx Japan 430% Vimpat vs. AED Market Growth (TDx) 425% 420% 10% +419% 5.6% 5% 0% AED Market Vimpat 2.5% 2.0% 1.5% 1.0% 424.9% Vimpat R3M TDx Share 2.2% +1.6% 0.5% 0.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data JP: IMS MIDAS - In-market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
17 Keppra 17 Reflecting both, the established brand and the maturity Net sales 1 For patients living with Epilepsy POS Epilepsy PGTCS Epilepsy myoclonic seizures million 9M M 2017 Act CER U.S % 4% Europe % -5% International markets % 13% Total Keppra % 5% 2018 Epilepsy GTCS: approval (China) Epilepsy monotherapy: approval (China) 2020 Patent expiry (Japan) 1 Numbers may not add due to rounding POS: Partial-onset seizures, also known as focal seizures CER: constant exchange rate PGTCS: Primary Generalized Tonic-Clonic Seizures GTCS: Generalized Tonic-Clonic Seizures
18 Keppra in-market performance 18 U.S. Europe Japan 5% 0% -5% -10% -15% Keppra vs. AED Market Growth (TRx) 1.1% AED Market Keppra -12.9% -11.8% 0% -5% -10% -15% Keppra vs. AED Market Growth (TDx) AED Market Keppra -2.1% -0.3% -2.4% 25% 20% 15% 10% 5% 0% Keppra vs. AED Market Growth (TDx) 20.6% +15% 5.6% AED Market Keppra Keppra R3M TRx Share -0.1% 0.7% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx Keppra R3M TDx Share 12.2% -0.3% 13.5% 13.0% 12.5% 12.0% 11.5% 11.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data EU: IMS MIDAS - In-Market KPI s are based on TDx 17.0% 16.5% 16.0% 15.5% Keppra R3M TDx Share 16.6% +1.6% 15.0% 14.5% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data JP: IMS MIDAS - In-market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
19 Briviact 19 Strong U.S. growth Net sales 1 million 9M M 2017 Act CER For patients living with Epilepsy POS 2 Adults, adolescents and children from 4 years of age (EU & U.S.) U.S % 99% Europe % 28% International markets 2 1 > 100% > 100% Total Briviact % 81% POS 2 : pediatric approval (U.S. & EU) Acute repetitive seizures: Phase 2 results Epilepsy POS 2 Phase 3 results (Japan) Patent expiry (U.S. & EU) 1 Numbers may not add due to rounding 2 POS: Partial-onset seizures, also known as focal seizures CER: constant exchange rate Acute repetitive seizures study NCT
20 Briviact in-market performance A new therapeutic option in the AED market 20 U.S. Europe Briviact R3M TRx Share Briviact R3M TDx Share 1.00% 0.80% 1.00% 0.80% 0.72% 0.60% 0.60% 0.40% 0.33% 0.40% +0.3% 0.20% +0.1% 0.00% Aug-17 Nov-17 Feb-18 May-18 Aug % 0.00% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data U.S.: U.S. IMS NPA In-Market KPIs are based on TRx Source data EU: IMS MIDAS In-Market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
21 Neupro 21 Stable at constant exchange rates Net sales 1 million 9M M 2017 Act CER For patients living with Parkinson s disease Restless legs syndrome U.S % 1% Europe % 5% International markets % -2% Total Neupro % 2% 2018 Parkinson s disease: approval (China) 2021 Patent expiry (U.S. & EU) 2024 Patent expiry (Japan) 1 Numbers may not add due to rounding CER: constant exchange rate
22 Neupro in-market performance 22 U.S. Europe Japan 20% Neupro PD vs. PD (KC) Market Growth (TRx) 20% Neupro PD vs. PD (KC) Market Growth (TDx) 20% Neupro PD vs. PD (KC) Market Growth (TDx) 17.1% 15% 10% 5% 0% -5% 7.5% 7.0% 6.5% -0.2% -0.2% PD market PD key competitors -3.2% Neupro PD R3M TRx Share -0.4% -3.4% Neupro 6.2% 6.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx 15% 10% 5% 0% -5% 16.5% 16.0% 15.5% -0.3% 4.8% 5.4% 5.1% PD Market PD key competitors Neupro PD R3M TDx Share Neupro +0.5% 16.0% 15.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data EU: IMS MIDAS - In-Market KPI s are based on TDx 15% 10% +18% 5% 0.8% 0% -5% -0.9% PD Market PD key Neupro competitors 37.0% 35.0% 33.0% 31.0% 29.0% Neupro PD R3M TDx Share +5.9% 34.7% 27.0% 25.0% Aug-17 Nov-17 Feb-18 May-18 Aug-18 Source data JP: IMS MIDAS - In-market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
23 Translating scientific hypotheses into clinical development 23 Phase 1 Phase 2 Phase 3 Filing Evenity (romosozumab) osteoporosis midazolam nasal spray acute repetitive seizures bimekizumab (IL17A/F) psoriasis psoriatic arthritis ankylosing spondylitis dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus Phase 3 program results Q Phase 3 to start Q Phase 3 to start Q Phase 2b results (Oct partner: Biogen) padsevonil (PPSI) highly drug-resistant epilepsy Phase 2b results H rozanolixizumab (FcRn) myasthenia gravis immune thrombocytopenia CIDP UCB6673 UCB7858 UCB0159 UCB0599 UCB0107 radiprodil (UCB3491) Phase 2a results (Oct 2018) Phase 2a results Q Phase 2 to start Q Bone Immunology Neurology Changes since February 2018: Midazolam acquired (April 2018) & filed (August 2018) UCB4144/VR942 available for license Seletalisib in Sjögren's Syndrome and APDS deprioritized UCB0107 first in human Evenity is the trade name of romosozumab which has been provisionally approved by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA). CIDP: Chronic inflammatory demyelinating polyneuropathy
24 R&D milestones romosozumab osteoporosis in post-menopausal women filing (EU) romosozumab resubmission (U.S.) rozanolixizumab myasthenia gravis Phase 2a results bimekizumab psoriatic arthritis Phase 3 start bimekizumab psoriasis Phase 3 results padsevonil high drug resistant epilepsy Phase 2b results padsevonil high drug resistant epilepsy Phase 2b start seletalisib dapirolizumab pegol SLE Phase 2b results bimekizumab ankylosing spondylitis Phase 3 start rozanolixizumab CIDP Phase 2 start UCB0107 Phase 1 start midazolam epilepsy filing (U.S.) rozanolixizumab ITP Phase 2a results rozanolixizumab myasthenia gravis confirmatory phase start neurology immunology bone SLE: Systemic Lupus Erythematosus ITP: Immune thrombocytopenia
25 Evenity (romosozumab) An innovative investigational bone-forming therapy 25 Dual effect on bone - increases bone formation and decreases bone resorption Opportunity to build new bone and slow bone loss in osteoporosis patients at imminent risk of fragility fractures Manorama, living with osteoporosis STRUCTURE, FRAME, BRIDGE and ARCH Phase 3 studies completed Under regulatory review in the U.S., Canada, Japan, Australia, Brazil and EU, Switzerland UCB and Amgen resubmitted Biologics License Application (BLA) to the U.S. FDA (July 2018) The trademark EVENITY is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). EVENITY (romosozumab) is developed in partnership with Amgen globally.
26 Translating scientific hypotheses into clinical differentiation Dual blockade of IL-17F and IL-17A by bimekizumab 26 IL-17A IL-17F IL-17RC IL-17RA IL-17F and IL-17A are twin cytokines driving joint and skin inflammation Dual blockade of IL-17F on top of IL-17A will improve therapeutic efficacy versus targeting IL-17A alone Bimekizumab specifically and completely blocks IL-17F and IL-17A
27 Bimekizumab Phase 3 development program in psoriasis 3 / 4 trials against active comparators - designed to demonstrate superiority 27 Phase 3 BE VIVID / PS0009 (NCT ) Phase 3 BE SURE / PS0008 (NCT ) Phase 3 BE READY / PS0013 (NCT ) Phase 3b BE RADIANT / PS0015 (NCT ) 560 patients living with psoriasis patients living with psoriasis patients living with psoriasis patients living with psoriasis 1 Duration 52 weeks 56 weeks 56 weeks 48 weeks Comparator Primary week 16 ustekinumab placebo PASI90 response IGA 0/1 response adalimumab PASI90 response IGA 0/1 response placebo PASI90 response IGA 0/1 response secukinumab PASI100 response Start Dec Results: Q Start Jan Results: Q Start Feb Results: Q Start June 2018 Results: moderate to severe chronic plaque psoriasis IGA: Investigator's Global Assessment PASI90: Patients experiencing at least 90% skin clearance Source: PASI100: Patients experiencing 100% skin clearance
28 Padsevonil Phase 2 program in drug-resistant focal epilepsy 28 Patient sub-group with high unmet medical need Phase 2a (NCT / EP0069 ) 55 patients with highly drugresistant focal epilepsy failed with 4 AED experiencing 4 seizures / week Phase 2b (NCT / ARISE / EP0091) 400 patients with drug-resistant focal epilepsy failed with 4 AED experiencing 4 seizures / month Comparator padsevonil / placebo (2 arms) padsevonil / placebo (5 arms) Endpoints 75 % responder rate* 31% padsevonil 11% placebo AES 2017 Seizure frequency from baseline over the 12 week maintenance period (U.S., Japan) 75% responder rate (EU) Results H * Proportion of subjects who achieve 75 % reduction in focal seizure frequency
29 Rozanolixizumab Phase 2a development program A first-in-class SubQ treatment for IgG-mediated diseases 29 Myasthenia gravis (NCT ) 43 patients with moderate to severe MG diagnosis of myasthenia screening be considered for treatment with immunological therapy Immune thrombocytopenia (NCT ) 66 patients with primary ITP 3 months screening Platelet count screening and baseline Chronic inflammatory demyelinating polyneuropathy Study design currently discussed with health authorities Duration 99 days 12 weeks Comparator placebo (2 arms) 5 arms Endpoints Change from baseline in Quantitative Myasthenia Gravis (QMG) score to visit 9 (day 29) Change from Baseline in Myasthenia Gravis- Composite score to Visit 9 Change from Baseline in Myasthenia Gravis- Activities of Daily Living (MGADL) score to Visit 9 Headline results (Oct 2018) Subjects experiencing at least one Treatment Emergent Event (TEAE) during the study Results Q interim results at ASH 2017 Phase 2 to start Q subq: sub-cutaneous IgG: immunoglobulin
30 Rozanolixizumab potential in multiple IgG autoantibodymediated diseases with high unmet medical need 30 Myasthenia gravis Immune thrombocytopenia Chronic inflammatory demyelinating polyneuropathy Antibodies target receptor sites of the neuromuscular junction Fatigue Muscle weakness (eyes, neck and jaws, respiratory muscles) Antibodies target platelets and destroy them Bruising Nosebleeds Purpura Intracranial bleeding Antibodies target components of peripheral nerves, causing damage to the myelin sheath Motor deficits Sensory deficits ~ cases / ~ cases / ~ 1-6 cases / Steroids Plasma exchange (PEX) IV immunoglobulin (IVIg) Surgery (thymectomy) Corticosteroids & thrombopoeitin IV immunoglobulin (IVIg) Surgery (splenectomy) Corticosteroids Plasma exchange (PEX) IV / subq immunoglobulin Current treatments partially stabilize the condition yet invasive, burdensome to patients & healthcare systems IV: Intravenous subq: sub-cutaneous
31 Now first in human: UCB0107, an anti-tau antibody for Progressive Supranuclear Palsy & Alzheimer s disease 31 Key facts UCB0107 blocks tau uptake and aggregation Tau misfolding and aggregation leads to neuronal death and disease spread PSP is a rare, rapidly progressing tauopathy with debilitating cognitive & motor symptoms Key insights UCB0107 was generated to block spreading of tau seeds from patient materials AD PSP Tau seeds spread from dying cells to infect other neurons Alzheimer s Disease is also a tauopathy, with high prevalence and economic impact Tau seed Source: UCB internal data AD: Alzheimer s disease PSP: Progressive Supranuclear Palsy
32 Tau misfolding leads to neuronal death and disease spread in AD and PSP 32 Release of tau seeds Microtubules stabilized by tau Hyperphosphorylation of tau causing destabilization of microtubules Release and accumulation of hyperphosphorylated tau Formation of tau oligomers Formation of neurofibrillary tangles (NFTs) Source: UCB internal data AD: Alzheimer s disease PSP: Progressive Supranuclear Palsy
33 Targeting tau spreading in early disease can delay or stop progression in AD and PSP 33
34 HY 2018 financials foundation for FY Core product growth drive top and bottom line Actual CER adjusted Revenue Revenue (adjusted for one-time revenue*) 2.27 billion 2.27 billion +2% +6% +4% Net sales 2.15 billion (+5%, +10% CER) Total operating expenses Overall operating expense ratio improved to 46% 1.04 billion -1% +4% R&D expenses phasing Recurring EBITDA Higher gross profit Improved operating expenses ratio 794 million +7% +12% +16% Profit of the Group 551 million attributable to UCB shareholders (+28%) Core earnings per share Based on 188 million weighted average shares outstanding (2017: 188 million) 574 million % +33% +22% +27% CER: constant exchange rate *one-time other revenue of 56 million for out-licensing the OTC-allergy drug Xyzal (levoceterizine) in 2017
35 Core product growth 35 Cimzia, Vimpat, Keppra, Briviact + Neupro = 87% of net sales Cimzia +2% (+11% CER) Sustainable growth in all regions Vimpat +10% (+20% CER) Strong growth in all markets HY 2018 net sales* million (+2%; CER: +10%) Keppra -5% (+2% CER) Reflecting both, the established brand and the maturity Briviact 60 million Strong U.S. growth Neupro -4% (0% CER) Stable at constant exchange rates CER = constant currency exchange rates * Excluding 65 million hedging
36 2018 HY report: recurring EBITDA Solid growth - Improved operating expenses ratio 36 For the six months ended 30 June Actual Variance million Actual rates CER Revenue % 6% Net sales % 10% Royalty income and fees % 6% Other revenue % -50% Gross profit % 7% Marketing and selling expenses % 2% Research and development expenses % 9% General and administrative expenses % -2% Other operating income / expenses (-) % -42% Total operating expenses % 4% Recurring EBIT (REBIT) % 11% Amortization of intangible assets % 6% Depreciation charges % 36% Recurring EBITDA (REBITDA) % 12% Numbers may not add due to rounding CER: constant exchange rate EBIT: Earnings before interest and taxes EBITDA: Earning before interests, taxes, depreciation and amortization charges
37 2018 HY report: profit 37 For the six months ended 30 June Actual Variance million Actual rates CER Recurring EBIT % 11% Impairment charges % -100% Restructuring expenses % -39% Gain on disposals 0 0 N/A N/A Other non-recurring income / expenses (-) 23 3 > 100% > 100% Total non-recurring income / expenses (-) 19 1 > 100% > 100% EBIT (operating profit) % 14% Net financial expenses (-) % -16% Result from associates -1 0 N/A N/A Profit before income taxes % 17% Income tax expense (-) / credit % -49% Profit from continuing operations % 33% Profit / loss (-) from discontinued operations % -62% Profit % 33% Attributable to UCB shareholders % 33% Attributable to non-controlling interests % 29% Profit attributable to UCB shareholders % 33% Numbers may not add due to rounding CER: constant exchange rate EBIT: Earnings before interest and taxes
38 2018 HY report: core earnings per share 38 Strong growth of core net profit For the six months ended 30 June Actual Variance million Actual rates CER Profit % 33% Attributable to UCB shareholders % 33% Attributable to non-controlling interests % 29% Profit attributable to UCB shareholders % 33% Total non-recurring income (-) / expenses > 100% > 100% Income tax on non-recurring expenses (-) / credit % -59% Financial one-off income (-) / expenses 0 0 N/A N/A Income tax on financial one-off income / expenses (-) 0 0 N/A N/A Profit (-) / loss from discontinued operations % -62% Amortization of intangibles linked to sales % 5% Income tax on amortization of intangibles linked to sales % -5% Core profit attributable to UCB shareholders % 27% Weighted average number of shares (million) % Core EPS attributable to UCB shareholders % 27% Numbers may not add due to rounding CER: constant exchange rate EPS: earnings per share
39 2018 HY report: key product net sales performance 39 P P P P For the six months ended 30 June Actual Variance million Actual rates CER Core products % 12% Immunology / CimziaP % 11% Neurology VimpatP % 20% KeppraP (including KeppraP XR + E KeppraP P) % 2% NeuproP % 0% BriviactP % 83% Established brands % -3% ZyrtecP (including Zyrtec-DP / CirrusP P) % -3% XyzalP % 0% Other products % -5% Net sales before hedging % 10% Designated hedges reclassified to net sales 65-8 > -100% Total net sales % 10% Numbers may not add due to rounding CER: constant exchange rate
40 One UCB today: A global player Presence in 38 countries complemented by a robust network of partners employees globally Situation at 30 June 2018
41 Stable shareholder base with free-float of 62% 41 Weighted average shares outstanding in 2018: 188 million Free float investors by region Source: Notifications, FactSet and UCB underlying ownership analysis, October 2018
42 Your UCB Investor Relations team 42 Antje Witte, Vice President Investor Relations Phone: antje.witte@ucb.com Neil Wallace, Director Investor Relations Phone: neil.wallace@ucb.com Isabelle Ghellynck, Director Investor Relations Check out our IR App stay Phone: tuned wherever you go isabelle.ghellynck@ucb.com Nathalie Deldime, Investor Relations Manager Phone: nathalie.deldime@ucb.com
UCB Inspired by patients. Driven by science.
UCB Inspired by patients. Driven by science. 3 months interim Report Brussels, 24 April 2017 Carolin, living with epilepsy and axial spondyloarthritis Disclaimer and safe harbor Forward-looking statements
More informationUCB Inspired by patients. Driven by science Half-Year Report Brussels, 26 July 2018
UCB Inspired by patients. Driven by science. 2018 Half-Year Report Brussels, 26 July 2018 Disclaimer and safe harbor Forward-looking statements 2 This presentation contains forward-looking statements,
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationUCB Inspired by patients. Driven by science Half-Year Results Brussels, 27 July 2017
UCB Inspired by patients. Driven by science. 2017 Half-Year Results Brussels, 27 July 2017 Disclaimer and safe harbor 2 Forward-looking statements This presentation contains forward-looking statements,
More informationUCB Inspired by patients. Driven by science full year financial report Brussels, 22 February 2018
UCB Inspired by patients. Driven by science. 2017 full year financial report Brussels, 22 February 2018 Disclaimer and safe harbor 2 Forward-looking statements This presentation contains forward-looking
More information2016 Half-Year Financial Results
2016 Half-Year Financial Results Brussels, 28 July 2016 Mariana, living with epilepsy Disclaimer and safe harbor Forward-looking statements 2 This presentation contains forward-looking statements, including,
More informationmonth interim update
2016 9 month interim update Brussels, 25 October 2016 Mariana, living with epilepsy Disclaimer and safe harbor Forward-looking statements 2016 9M interim update - 2 This presentation contains forward-looking
More informationUCB Inspired by patients. Driven by science.
UCB Inspired by patients. Driven by science. Jean-Christophe Tellier, CEO Full Year 2016 Results Presentation Brussels, 23 February 2017 Carolin, living with epilepsy and axial spondyloarthritis Disclaimer
More informationUCB presentation. Investor Relations April 24, 2014
UCB presentation Investor Relations April 24, 2014 Disclaimer and safe harbor 2 Forward-looking statements: This presentation contains forward-looking statements based on current plans, estimates and beliefs
More information2013 half-year results. 31 July 2013
2013 half-year results 31 July 2013 Disclaimer and safe harbour 2 Forward-looking statements: This presentation contains forward-looking statements based on current plans, estimates and beliefs of management.
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationUCB: creating value for patien ts. Company Overview Oct. 2017
UCB: creating value for patien ts Company Overview Oct. 2017 UCB: reinventing itself, leveraging a solid heritage 2 1928: Emmanuel Janssen establishes UCB in Brussels 1972: A new stateof-the-art R&D center
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationEnhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationcandidiasis and nasopharyngitis. No cases of suicidal ideation/behavior, major adverse cardiac events, or inflammatory bowel disease were reported.
Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study 80 to 100% of BE ABLE 1 responders maintained a
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationDUPIXENT FDA Approval Call March 28, 2017
DUPIXENT FDA Approval Call March 28, 2017 1 Sanofi Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as
More informationThe next generation biopharma leader
The next generation biopharma leader Half Year 2008 Results UCB Group Analysts and Investors Presentation Lloyd and Alexander, living with epilepsy August 1, 2008 Disclaimer and safe harbour 2 Forward-looking
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationUCB receives positive EU CHMP opinion for CIMZIA (certolizumab pegol) AutoClicks Prefilled Pen
UCB receives positive EU CHMP opinion for CIMZIA (certolizumab pegol) AutoClicks Prefilled Pen Brussels, Belgium September, 2016 UCB has announced that the European Medicines Agency s (EMA s) Committee
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationPublication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationDainippon Sumitomo Pharma
Progressing Towards an Internationally Competitive R&D-Oriented Pharmaceutical Company Dainippon Sumitomo Pharma Masayo Tada President and CEO 29th Annual J.P. Morgan Healthcare Conference January 11,
More informationNew long-term data on Cimzia (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis
New long-term data on Cimzia (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis For the attention of European journalists only New 96-week interim
More informationEisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai s In-house Discovered Anticancer Agent LENVIMA Eisai Conference for Media and
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationProthena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationNomura Healthcare Conference
Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011 Forward Looking Statements 2 This presentation contains forward-looking statements as defined in the Private
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More information2010 full-year results 2 March 2011
2010 full-year results 2 March 2011 Progressing to become the patient-centric global biopharma leader Alison, living with rheumatoid arthritis Disclaimer and safe harbour Forward-looking statements: This
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationBank of America Merrill Lynch Global Healthcare Conference 2012
Bank of America Merrill Lynch Global Healthcare Conference 2012 Shire plc September 12, 2012 Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationUCB enhances epilepsy presence in Japan and China: positive Phase 3 study for VIMPAT
UCB enhances epilepsy presence in Japan and China: positive Phase 3 study for VIMPAT Phase 3 study evaluating VIMPAT as adjunctive therapy in the treatment of Japanese and Chinese adult patients with partial-onset
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More information